经过8%的收入增长, Zoetis 提高了第二季度的预期, 收入达到236亿美元, 超过分析师的预期.
Zoetis raises FY guidance after 8% revenue increase to $2.36bn in Q2, beating analyst expectations.
动物药品制造商Zoetis在伴侣动物产品组合的销售强之后提高了全年预期.
Zoetis, a veterinary drug maker, raised its full-year guidance following strong sales in its companion animal portfolio.
公司报告收入增长8%至236亿美元,净利为6.24亿美元,高于去年同期的6.71亿美元.
The company reported a 8% revenue increase to $2.36bn and net income of $624m for Q2, up from $671m in the same period last year.
调整后的收益为每股1.56美元,超过分析师的预期。
Adjusted earnings were $1.56 per share, surpassing analyst expectations.
该公司预计,每股年收入在5.35至5.45美元之间,每股年收入在9.1bn至9.25bn之间。
The company anticipates full-year earnings per share between $5.35 and $5.45 and revenue between $9.1bn and $9.25bn.